Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $17.40 million. The enterprise value is -$5.61 million.
| Market Cap | 17.40M |
| Enterprise Value | -5.61M |
Important Dates
The last earnings date was Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 8.24 million shares outstanding. The number of shares has increased by 22.05% in one year.
| Current Share Class | 8.24M |
| Shares Outstanding | 8.24M |
| Shares Change (YoY) | +22.05% |
| Shares Change (QoQ) | +20.93% |
| Owned by Insiders (%) | 4.53% |
| Owned by Institutions (%) | 24.29% |
| Float | 6.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.08 |
| Forward PS | 39.18 |
| PB Ratio | 0.80 |
| P/TBV Ratio | 0.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.48, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.48 |
| Quick Ratio | 11.39 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -60.94% and return on invested capital (ROIC) is -39.87%.
| Return on Equity (ROE) | -60.94% |
| Return on Assets (ROA) | -37.04% |
| Return on Invested Capital (ROIC) | -39.87% |
| Return on Capital Employed (ROCE) | -57.74% |
| Weighted Average Cost of Capital (WACC) | 6.68% |
| Revenue Per Employee | $112,104 |
| Profits Per Employee | -$846,529 |
| Employee Count | 14 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $200 in taxes.
| Income Tax | 200 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.02% in the last 52 weeks. The beta is 0.46, so Lipocine's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -30.02% |
| 50-Day Moving Average | 2.25 |
| 200-Day Moving Average | 4.55 |
| Relative Strength Index (RSI) | 43.39 |
| Average Volume (20 Days) | 41,347 |
Short Selling Information
The latest short interest is 110,962, so 1.35% of the outstanding shares have been sold short.
| Short Interest | 110,962 |
| Short Previous Month | 123,024 |
| Short % of Shares Out | 1.35% |
| Short % of Float | 1.61% |
| Short Ratio (days to cover) | 2.96 |
Income Statement
In the last 12 months, Lipocine had revenue of $1.57 million and -$11.85 million in losses. Loss per share was -$1.82.
| Revenue | 1.57M |
| Gross Profit | 1.57M |
| Operating Income | -12.57M |
| Pretax Income | -11.85M |
| Net Income | -11.85M |
| EBITDA | -12.51M |
| EBIT | -12.57M |
| Loss Per Share | -$1.82 |
Balance Sheet
The company has $23.27 million in cash and $257,807 in debt, with a net cash position of $23.01 million or $2.79 per share.
| Cash & Cash Equivalents | 23.27M |
| Total Debt | 257,807 |
| Net Cash | 23.01M |
| Net Cash Per Share | $2.79 |
| Equity (Book Value) | 21.77M |
| Book Value Per Share | 2.64 |
| Working Capital | 21.67M |
Cash Flow
| Operating Cash Flow | -11.19M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 58,566 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.19M |
| FCF Per Share | -$1.36 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -800.82% |
| Pretax Margin | -755.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.05% |
| Shareholder Yield | -22.05% |
| Earnings Yield | -68.13% |
| FCF Yield | -64.33% |
Analyst Forecast
The average price target for Lipocine is $6.00, which is 184.36% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 184.36% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | -15.33% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
Lipocine has an Altman Z-Score of -5.64 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.64 |
| Piotroski F-Score | 1 |